- Home
- PBYI vs MHLD Comparison
PBYI vs MHLD Comparison
Compare PBYI & MHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- MHLD
- Stock Information
- Founded
- PBYI 2010
- MHLD 2007
- Country
- PBYI United States
- MHLD Bermuda
- Employees
- PBYI N/A
- MHLD N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- MHLD Property-Casualty Insurers
- Sector
- PBYI Health Care
- MHLD Finance
- Exchange
- PBYI Nasdaq
- MHLD Nasdaq
- Market Cap
- PBYI 153.2M
- MHLD 137.1M
- IPO Year
- PBYI N/A
- MHLD 2008
- Fundamental
- Price
- PBYI $2.97
- MHLD $1.21
- Analyst Decision
- PBYI Strong Buy
- MHLD
- Analyst Count
- PBYI 1
- MHLD 0
- Target Price
- PBYI $7.00
- MHLD N/A
- AVG Volume (30 Days)
- PBYI 821.3K
- MHLD 249.9K
- Earning Date
- PBYI 02-27-2025
- MHLD 03-11-2025
- Dividend Yield
- PBYI N/A
- MHLD N/A
- EPS Growth
- PBYI 492.79
- MHLD N/A
- EPS
- PBYI 0.47
- MHLD N/A
- Revenue
- PBYI $243,569,000.00
- MHLD $89,074,000.00
- Revenue This Year
- PBYI N/A
- MHLD N/A
- Revenue Next Year
- PBYI N/A
- MHLD N/A
- P/E Ratio
- PBYI $6.38
- MHLD N/A
- Revenue Growth
- PBYI 6.30
- MHLD 20.80
- 52 Week Low
- PBYI $2.23
- MHLD $1.16
- 52 Week High
- PBYI $7.73
- MHLD $2.27
- Technical
- Relative Strength Index (RSI)
- PBYI 45.95
- MHLD 43.16
- Support Level
- PBYI $2.92
- MHLD $1.16
- Resistance Level
- PBYI $4.06
- MHLD $1.33
- Average True Range (ATR)
- PBYI 0.27
- MHLD 0.13
- MACD
- PBYI -0.03
- MHLD 0.00
- Stochastic Oscillator
- PBYI 4.39
- MHLD 9.09
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.